SUMMARY In a prospective study of 466 X chromatin positive males an increase in mortality of about 500/%, has been observed. The increase is associated with a loss of about five years in life span. There is no convincing evidence that the increase is concentrated at any particular age group but this possibility could not be excluded. No effect of mode of ascertainment could be demonstrated. From this study we conclude that it is likely that the mortality experienced by chromatin positive males in general is at least 1150% of that experienced by normal men and could be more than 200%.
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One or two males in every thousand of the male population have a female nuclear X chromatin (chromatin positive) pattern.1 They have an abnormality of the sex chromosome constitution,2 the essential feature of which is the presence of at least one additional X chromosome, the usual complete chromosome complement being 47,XXY.4 Affected men usually present in adult life because of infertility and hypergonadotrophic hypogonadism. A proportion also have gynaecomastia (Klinefelter's syndrome).5 There is an increased risk of mental retardation and about one in every hundred institutionalised high grade retardates are chromatin positive.6 The chromatin positive status can be recognised from early embryonic life but the condition is only rarely diagnosed clinically in infancy and childhood. There is, however, evidence of an increased infant mortality, and in a study of 296 male infant deaths in Moscow, Bochkov7 found 10 chromatin positive males, while in studies of liveborn males in the UK, USA, and Canada,8-'0 six infant deaths, mostly in the immediate postnatal period, have been reported in a total of 111 babies with a 47,XXY chromosome complement. The prevailing national infant mortality rates at the time of these studies were in the region of 20 per thousand. There is no published information on mortality in chromatin positive males after the first year of life.
In 1959 Professor W M Court-Brown set up in Edinburgh a register of subjects with chromosome abnormalities. One of the main objects was a long term prospective mortality study. Since (table 4) . Because this group was older at ascertainment than group I, the expected number of deaths is higher (27.6) despite the fewer years of follow up. The observed deaths are significantly raised at 44 (p<0.01), an increase in mortality of 590/,, the 950/u confidence limits for relative mortality being 1-15 to 2-14. Only one of this group was lost to follow up.
The 66 individuals in group Illa experienced 35 deaths, far in excess of the expected figure of 9-7. In view of the totally biased mode of ascertainment (with respect to mortality) no further analysis has been undertaken.
Of the individuals ascertained because of physical illness, we felt that only 24 were at no risk of increased mortality (group IlIb). The expected number of deaths in this subgroup was 2-9 and the actual deaths 6 (table 5). The small sample prevents further useful analysis.
Patients in groups I and Illb were ascertained because of non life threatening conditions. It is likely that they were drawn from the same pool of KS subjects in the population. We feel it is reasonable to combine the data from these groups to assess the risk of mortality to KS patients in the general population. This produces an expected number of 22-7 and actual number of 34 deaths. This increase is significant (p<0.05), and the 95u/, confidence limits for the relative mortality are 1-03-2-09. We were unable to demonstrate any difference between this combined group and group II in terms of mortality (X2 = 0.24), but as the modes of ascertainment are so disparate, it 35 Mortality ratios and life expectancy in X chromatin positive males may not be justifiable to combine the data from all age 1 year, of about five years ( Within each ascertainment group, there is considerable karyotypic heterogeneity. The most common karyotype is 47,XXY, and most of the other karyotypes are so rare in the community that it is unlikely that epidemiological data will ever be available for each individually.
The causes of death among the KS patients included in this study and a comparison with expected mortalities from these causes will be described in a later publication. The calculation of the "normal" survival curve presented a problem. Our group of chromatin positive men were acquired from two populations (England and Scotland) known to have different mortality rates. Further different age cohorts within these populations have been exposed to very different risks. The problem was solved by developing a theoretical control group. As each chromatin positive man was entered into the study, a theoretical man of exactly the same age was acquired into the control group. The control individual suffered precisely the death rate published by the Registrars General in that, if his probability of surviving to enter the k'th age group/calendar year element was x, then his probability of entering the next element wasxe-', where p is the published death rate and t the length of time he would spend in the element if he did not die.This individual therefore contributes x(1-es') deaths to the element and x(1 -ePt)Ip years at risk. The total number of deaths for the control group in each age group was calculated by summing each individual's contribution. Similarly, the control "years at risk" was calculated by addition. These figures were used to define a survival curve in exactly the same way as for the observed groups. Since the theoretical control group is representative of the population at large (given that it is identical with the observed group in birth date, sex, and geographical area) we can neglect sampling error and so no confidence limits are quoted for the control survival curve.
Expectation of life, at any age, was estimated from the life curve by calculation of the area under the survival curve beyond that age and dividing by the surviving fraction at that age.
